Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Imcivree Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Imcivree Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization, renewal authorization, and quantity-limit exceptions for Imcivree (setmelanotide acetate) 10 mg/mL subcutaneous solution for commercial Boeing members, including approved or supported genetic, syndromic, and acquired hypothalamic obesity indications.

    Policy Summary
    PayerPrime Therapeutics
    PolicyImcivree Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit medical records supporting the diagnosis and required genetic or clinical documentation with the authorization request.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial approval duration
    12 monthsRenewal approval duration
    10 vials/30 daysQuantity limit
    ≥5%Renewal clinical benefit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    Genetic deficiency categories
    4 or 3+2BBS feature combinations

    Coverage Criteria

    Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's Prior Authorization process.

      Patients not previously approved for the requested agent require initial evaluation review.

    • ONE of the following

      • ONE of the following

        • For adult patients, the patient has had a greater than or equal to 5% reduction from baseline body weight prior to therapy with the requested agent.>= 5% reduction from baseline body weight
        • For patients with growth potential, the patient has had a greater than or equal to 5% reduction from baseline BMI prior to therapy with the requested agent.>= 5% reduction from baseline BMI
      • ALL of the following

        • The patient has a diagnosis other than hypothalamic obesity (HO), Bardet-Biedl syndrome (BBS), or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency.
        • The patient has had clinical benefit with the requested agent.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist, or metabolic disorders specialist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient does not have any FDA-labeled contraindications to the requested agent.

    Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • ALL of the following

        • The patient has a diagnosis of monogenic obesity due to pro-opiomelanocortin (POMC) deficiency, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, or leptin receptor (LEPR) deficiency.
        • Genetic testing with an FDA-approved test has confirmed variants in the POMC, PCSK1, or LEPR genes.

          Medical records required.

        • The patient's genetic status is bi-allelic, homozygous, or compound heterozygous (not double heterozygous).
        • The patient's genetic variant is interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).

    Quantity-Limit Exception

    The requested quantity (dose) above the program quantity limit is covered when the qualifying condition below is met:

    ONE of the following

    • The requested quantity (dose) does not exceed the program quantity limit.
    • ALL of the following

      • The requested agent does not have a maximum FDA-labeled dose for the requested indication.
      • There is support for therapy with a higher dose for the requested indication.
    • ALL of the following

      • The requested quantity (dose) does not exceed the maximum FDA-labeled dose for the requested indication.

    Clinical Thresholds

    Adult obesity threshold
    PopulationAdult patients
    ThresholdBMI greater than or equal to 30 kg/m²
    AssessmentBody mass index (BMI)
    Pediatric obesity threshold
    PopulationPediatric patients
    ThresholdWeight greater than or equal to the 95th percentile
    Assessment basisStandardized growth chart assessments

    Authorization and Documentation Requirements

    Prior Authorization

    Obtain initial prior authorization

    Initial approval requires all applicable criteria to be met: an eligible diagnosis pathway, applicable age and obesity requirements, specialist involvement or consultation, and no FDA-labeled contraindication. Eligible pathways include monogenic obesity due to POMC, PCSK1, or LEPR deficiency, Bardet-Biedl syndrome, acquired hypothalamic obesity, or another FDA-labeled indication for the requested agent and route.

    • Adults: BMI greater than or equal to 30 kg/m².
    • Pediatric patients: weight greater than or equal to the 95th percentile based on standardized growth chart assessments.
    • The prescriber must be a specialist in the diagnosis area or have consulted with one.
    Prior Authorization

    Secure renewal authorization

    Renewal requires prior approval through the plan's prior authorization process, documented clinical benefit, specialist involvement or consultation, and absence of FDA-labeled contraindications. Patients without previous plan approval require initial evaluation review.

    Policy Background

    Imcivree (setmelanotide) is covered under this policy for obesity associated with specified genetic deficiencies, Bardet-Biedl syndrome, acquired hypothalamic obesity, or another FDA-labeled indication for the requested agent and route of administration. Qualifying genetic deficiencies include POMC, PCSK1, or LEPR deficiency; applicable genetic or clinical documentation is required.

    The policy applies to eligible adult and pediatric patients when applicable age and obesity requirements are met. For adults, obesity is defined as BMI ≥30 kg/m²; for pediatric patients, weight must be ≥ the 95th percentile based on standardized growth chart assessments. Initial and renewal authorization also require specialist involvement or consultation and absence of FDA-labeled contraindications.

    Key Definitions

    Bi-allelic, homozygous, or compound heterozygous
    Relevant variantPresent on both alleles
    Included genetic statusesThe same variant on both alleles (homozygous) or two different variants in the same gene (compound heterozygous)
    Excluded statusDouble heterozygous status is excluded
    Clinical diagnosis of BBS
    ConditionBardet-Biedl syndrome (BBS)
    Primary-feature pathwayFour primary features
    Combined-feature pathwayThree primary features plus two secondary features

    Imcivree Initial Therapy

    Imcivree Initial Therapy

    Initial therapy is approved when ALL applicable criteria are met.

    Initial Imcivree therapy

    • Eligible diagnosis

      • Monogenic obesity due to POMC, PCSK1, or LEPR deficiency: The patient has monogenic obesity due to POMC deficiency, PCSK1 deficiency, or LEPR deficiency; FDA-approved genetic testing confirms a variant in the relevant gene; genetic status is bi-allelic, homozygous, or compound heterozygous and not double heterozygous; the variant is pathogenic, likely pathogenic, or a variant of uncertain significance; and the variant is not benign or likely benign.

        Medical records supporting the genetic testing are required.

      • Bardet-Biedl syndrome

        • BBS clinical feature criteria: The patient has four primary features, or three primary features and two secondary features.

    Imcivree Renewal

    Imcivree Renewal

    Renewal is approved when ALL of the following are met.

    Imcivree renewal

    • Prior approval: The patient was previously approved for the requested agent through the plan's prior authorization process.

      Patients without prior plan approval require initial evaluation review.

    • Clinical benefit

      • Adult clinical benefit: The patient has achieved a reduction of at least 5% from baseline body weight.>=5% reduction
      • Clinical benefit in patients with growth potential:

    Program Quantity Limit

    Quantity limit
    ProductImcivree (setmelanotide acetate) 10 mg/mL vials
    Program quantity limit10 vials
    Time periodPer 30 days
    Policy Summary
    PayerPrime Therapeutics
    PolicyImcivree Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit medical records supporting the diagnosis and required genetic or clinical documentation with the authorization request.
    SourceLink
    On This Page
    Coverage CriteriaClinical ThresholdsAuthorization and Documentation RequirementsPolicy BackgroundKey DefinitionsImcivree Initial TherapyImcivree RenewalProgram Quantity Limit
  1. The patient's genetic variant is not classified as benign or likely benign.
  2. ALL of the following

    • The patient has a diagnosis of syndromic obesity due to Bardet-Biedl syndrome (BBS).
    • ONE of the following

      • Clinical diagnosis of BBS based on four primary features or three primary and two secondary features.

        Medical records required. Primary features include rod-cone dystrophy, polydactyly, obesity, genital anomalies, renal anomalies, and learning difficulties. Secondary features include speech delay, developmental delay, diabetes mellitus, dental anomalies, congenital heart disease, brachydactyly/syndactyly, ataxia/poor coordination, and anosmia/hyposmia.

      • Confirmation of a pathogenic or likely pathogenic variant in a gene known to be associated with BBS.

        Medical records required.

  3. ALL of the following

    • The patient has a diagnosis of acquired hypothalamic obesity (HO).
    • The patient has hypothalamic injury or lesion (e.g., surgery, radiation, tumors affecting the hypothalamus, or other traumatic brain injury).

      Medical records required.

    • The patient has rapid weight gain associated with hypothalamic injury and not primarily due to another condition (e.g., Prader-Willi syndrome or ROHHADNET).
  4. The patient has another FDA-labeled indication for the requested agent and route of administration.
  5. ONE of the following, if the patient has an FDA-labeled indication

    • The patient's age is within FDA labeling for the requested indication for the requested agent.
    • There is support for using the requested agent for the patient's age for the requested indication.
  6. ONE of the following

    • For adult patients, the body mass index (BMI) is greater than or equal to 30 kg/m².>= 30 kg/m²
    • For pediatric patients, weight is greater than or equal to the 95th percentile based on standardized growth chart assessments.>= 95th percentile
  7. The prescriber is a specialist in the area of the patient's diagnosis (e.g., endocrinologist, geneticist, or metabolic disorders specialist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
  8. The patient does not have any FDA-labeled contraindications to the requested agent.
  9. There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
    Adult renewal clinical benefit
    PopulationAdult patients receiving renewal authorization
    Required benefitGreater than or equal to 5% reduction from baseline body weight
    BaselineBody weight measured before therapy with the requested agent
    Growing-patient renewal clinical benefit
    PopulationPatients with growth potential receiving renewal authorization
    Required benefitGreater than or equal to 5% reduction from baseline BMI
    BaselineBMI measured before therapy with the requested agent
    • Adults must demonstrate at least a 5% reduction from baseline body weight, or patients with growth potential must demonstrate at least a 5% reduction from baseline BMI.
    • The prescriber must be a specialist in the diagnosis area or have consulted with one.
    Documentation Required

    Submit diagnosis and genetic documentation

    Submit medical records supporting the diagnosis. For monogenic obesity, provide genetic testing from an FDA-approved test confirming a relevant POMC, PCSK1, or LEPR variant; for Bardet-Biedl syndrome, provide records supporting the required clinical features or a pathogenic or likely pathogenic associated gene variant.

    • For monogenic obesity, document bi-allelic, homozygous, or compound heterozygous status, excluding double heterozygous status.
    • For acquired hypothalamic obesity, document the hypothalamic injury or lesion and rapid associated weight gain not primarily due to another condition.
    Documentation Required

    Document response for renewal

    For renewal, document prior plan approval and clinical benefit using measurements obtained before therapy with the requested agent as the baseline. Provide baseline and current body weight for adults or baseline and current BMI for patients with growth potential.

    • Adults: document a reduction of at least 5% from baseline body weight.
    • Patients with growth potential: document a reduction of at least 5% from baseline BMI.
    Documentation Required

    Support quantity-limit exceptions

    For a quantity-limit exception, provide support for the higher dose when no maximum FDA-labeled dose exists for the indication, or explain why the requested quantity cannot be achieved with a lower quantity of a higher-strength product within the program quantity limit.

    • If no maximum FDA-labeled dose exists, support therapy with the requested higher dose.
    • If a maximum FDA-labeled dose applies, show that the requested quantity does not exceed it and explain why a lower quantity of a higher-strength product cannot be used within the limit.
    Denial Risk

    Avoid initial-criteria denial

    Initial authorization may be denied when the patient does not meet an eligible diagnosis pathway or applicable age and obesity requirements, required genetic or clinical documentation is absent, specialist involvement or consultation is not established, or an FDA-labeled contraindication is present.

    • Genetic variants classified as benign or likely benign do not meet the specified monogenic obesity criteria.
    • Genetic status that is double heterozygous does not meet the specified requirement.
    Denial Risk

    Avoid renewal-criteria denial

    Renewal may be denied when the patient was not previously approved through the plan's prior authorization process, required clinical benefit is not demonstrated, specialist involvement or consultation is absent, or an FDA-labeled contraindication exists.

    • Adults must show at least a 5% reduction from baseline body weight, or patients with growth potential must show at least a 5% reduction from baseline BMI, unless the applicable other-diagnosis clinical-benefit pathway is met.
    Denial Risk

    Avoid unsupported quantity-limit override

    A quantity-limit exception may be denied when the requested dose exceeds the program limit without support for a higher dose or without documentation that the requested quantity cannot be achieved using a lower quantity of a higher-strength product within the limit.

    • For an indication without a maximum FDA-labeled dose, support for therapy with the higher dose is required.
    • When a maximum FDA-labeled dose applies, the requested quantity must not exceed that dose and the alternative lower-quantity, higher-strength option must be shown to be unsuitable within the program limit.
    Primary featuresRod-cone dystrophy, polydactyly, obesity, genital anomalies, renal anomalies, and learning difficulties
    Secondary featuresSpeech delay, developmental delay, diabetes mellitus, dental anomalies, congenital heart disease, brachydactyly/syndactyly, ataxia or poor coordination, and anosmia or hyposmia
    Acquired hypothalamic obesity
    DefinitionObesity resulting from hypothalamic injury or lesion
    Examples of causesSurgery, radiation, tumors affecting the hypothalamus, or other traumatic brain injury
    Associated findingRapid weight gain associated with the hypothalamic injury
    ExclusionThe rapid weight gain is not primarily caused by another condition, such as Prader-Willi syndrome or ROHHADNET
    4 primary OR 3 primary + 2 secondary

    Primary features include rod-cone dystrophy, polydactyly, obesity, genital anomalies, renal anomalies, and learning difficulties. Secondary features include speech delay, developmental delay, diabetes mellitus, dental anomalies, congenital heart disease, brachydactyly/syndactyly, ataxia/poor coordination, and anosmia/hyposmia. Medical records are required.

  10. BBS genetic confirmation: A pathogenic or likely pathogenic variant is confirmed in a gene known to be associated with Bardet-Biedl syndrome.

    Medical records are required.

  11. Acquired hypothalamic obesity: The patient has acquired hypothalamic obesity with documented hypothalamic injury or lesion and rapid weight gain associated with the injury that is not primarily due to another condition.

    Examples of hypothalamic injury or lesion include surgery, radiation, tumors affecting the hypothalamus, or other traumatic brain injury. Examples of other conditions include Prader-Willi syndrome and ROHHADNET. Medical records are required.

  12. Other FDA-labeled indication: The patient has another FDA-labeled indication for the requested agent and route of administration.
  13. Age requirement when an FDA-labeled indication is used: The patient's age is within FDA labeling for the requested indication, or there is support for using the requested agent for the patient's age and indication.
  14. Obesity threshold: The patient meets the applicable obesity threshold.Adults: BMI >= 30 kg/m² OR pediatric patients: weight >= 95th percentile based on standardized growth chart assessments
  15. Specialist involvement: The prescriber is a specialist in the area of the patient's diagnosis, or the prescriber has consulted with such a specialist.

    Examples include endocrinology, genetics, or metabolic disorders.

  16. Contraindication screening: The patient does not have any FDA-labeled contraindications to the requested agent.
  17. The patient has achieved a reduction of at least 5% from baseline BMI.
    >=5% reduction
  18. Other diagnosis with clinical benefit: The patient has a diagnosis other than hypothalamic obesity, Bardet-Biedl syndrome, or POMC, PCSK1, or LEPR deficiency and has had clinical benefit with the requested agent.
  19. Specialist involvement: The prescriber is a specialist in the area of the patient's diagnosis, or the prescriber has consulted with such a specialist.

    Examples include endocrinology, genetics, or metabolic disorders.

  20. No FDA-labeled contraindication: The patient does not have any FDA-labeled contraindications to the requested agent.